Johnson & Johnson Committing $500 Million To HIV, TB Fight
04 October 2019 - 10:33PM
Dow Jones News
By Chris Wack
Johnson & Johnson (JNJ) said Friday it is committing more
than $500 million to research and development and delivery programs
over the next four years to accelerate global efforts to eliminate
HIV and tuberculosis by 2030.
The health-care company said it will dedicate a team of
researchers to accelerate the discovery, development and delivery
of next generation medicines and vaccines to complement investments
being made by governments.
"No single institution can tackle the historic challenge of
eliminating an infectious disease," said Paul Stoffels, chief
scientific officer at Johnson & Johnson.
As part of the $500 million investment, the Janssen
Pharmaceutical Cos. of Johnson & Johnson will continue to
advance an investigational mosaic-based vaccine regimen to prevent
HIV together with a consortium of partners.
The company said an ongoing efficacy trial in 2,600 women in
southern Africa is fully enrolled. A second efficacy trial is about
to begin in North America, South America and Europe with 3,800 men
who have sex with men and transgender individuals.
In partnership with ViiV Healthcare, Janssen also is working on
a long-acting injectable HIV treatment regimen that could be
administered to patients once every two months. This regimen, if
approved, could potentially reduce HIV treatment for some patients
to just 12 or even six injection visits per year to keep the virus
under control, instead of a daily oral treatment taken 365 times a
year.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 04, 2019 08:18 ET (12:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024